Zio by iRhythm Technologies, Inc. news
iRhythm President and CEO Quentin Blackford sat down with Nasdaq’s Behind the Bell to discuss iRhythm’s patient-first mission to impact people across the globe, the opportunity to advance our innovative platform technology, and Nasdaq’s role in realizing our vision.<
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the results of four clinical studies presented at the American Heart Association’s (
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced a new health economic analysis of the
iRhythm Technologies will have the results of four studies presented by leading clinical investigators at the American Heart Association’s 2022 Scientific Sessions on Nov. 5-7 in Chicago, Illinois. The studies listed below focus on iRhythm’s core suite of Zio XT and AT patch-based extended and mobile cardiac monitoring products and services.
Saturday, Nov. 5
- 3:00 – 4:00 p.m. CDT – SA4182: “Ascension Health Syst
iRhythm is included in the Medtech Big 100, a ranking of the world’s largest medical device companies, for the second year in a row. Medical Design & Outsourcing says it evaluates companies for the list based on annual revenue, research and development spending, number of employees, key leaders, headquarters locations, and company descriptions.
Read the
iRhythm was recently named to the San Francisco Business Times Middle Market 75 list, which features fast-growing companies headquartered in the Greater Bay Area. Selection was based on a weighted formula that takes into account both absolute revenue growth along with percentage revenue growth. This is a premier list of agile, strategic, and forward-thinking companies.
See the
iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced it received FDA 510(k) clearance for its ZEUS (Zio ECG Utilization Software) System for the Zio Watch. Produced in partnership with Verily, an Alphabet precis
iRhythm Technologies, Inc. is excited to announce the addition of a Clinical Resource Center (CRC) to its website. The CRC was des
- iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices.
- One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to monitor patients after discharge, the physicians reduced hospital stays and potentially improved identification of arrhythmia by extending monitori
More than a decade after first earning the FDA’s sign-off for its Zio ECG patch, iRhythm is still churning out data to prove beyond a shadow of a doubt the heart monitor’s ability to spot atrial fibrillation and other arrhythmias as early as possible. The latest bit of proof came in the form of a trio of studies presented at the American College of Cardiology’s annual scientific meeting.
The research shows that the two-week, artificial intelligence-powered Zio system